SFI
EIGR

Susquehanna Fundamental Investments’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-789
Closed -$209K – 1815
2021
Q1 		$209K Sell
789
-473
-37% -$149K ﹤0.01% 1383
2020
Q4 		$465K Sell
1,262
-101
-7% -$29K 0.01% 1132
2020
Q3 		$333K Buy
1,363
+1,016
+293% +$316K 0.01% 1022
2020
Q2 		$100K Buy
+347
New +$102K ﹤0.01% 903

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna Fundamental Investments's EIGR Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2021, closing a stake of 789 shares — an estimated $209K sold.

Susquehanna Fundamental Investments first reported a position in EIGR in Q2 2020 and held it in 4 quarters. The position peaked at $465K in Q4 2020. 90 funds tracked by Wall St. Rank hold EIGR as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 789 Eiger BioPharmaceuticals, Inc. shares in Q2 2021, an estimated $209K.
  • Susquehanna Fundamental Investments first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Eiger BioPharmaceuticals, Inc. position peaked at $465K in Q4 2020.
  • 90 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.